BlackRock’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-13,850,498
| Closed | -$52.6M | – | 5200 |
|
|
2020
Q1 | $52.6M | Sell |
13,850,498
-438,426
| -3% | -$1.89M | ﹤0.01% | 2010 |
|
|
2019
Q4 | $72.7M | Buy |
14,288,924
+567,969
| +4% | +$3M | ﹤0.01% | 2141 |
|
|
2019
Q3 | $69.4M | Sell |
13,720,955
-21,719
| -0.2% | -$108K | ﹤0.01% | 2097 |
|
|
2019
Q2 | $84.8M | Buy |
13,742,674
+209,687
| +2% | +$1.01M | ﹤0.01% | 2015 |
|
|
2019
Q1 | $62.8M | Buy |
13,532,987
+2,224
| +0% | +$10.1K | ﹤0.01% | 2151 |
|
|
2018
Q4 | $56.8M | Buy |
13,530,763
+237,520
| +2% | +$1.21M | ﹤0.01% | 2160 |
|
|
2018
Q3 | $83.3M | Buy |
13,293,243
+1,902,006
| +17% | +$14.6M | ﹤0.01% | 2084 |
|
|
2018
Q2 | $91.6M | Buy |
11,391,237
+1,401,564
| +14% | +$10.7M | ﹤0.01% | 2003 |
|
|
2018
Q1 | $74.5M | Sell |
9,989,673
-7,068
| -0.1% | -$47K | ﹤0.01% | 2029 |
|
|
2017
Q4 | $59.5M | Buy |
9,996,741
+202,932
| +2% | +$1.23M | ﹤0.01% | 2177 |
|
|
2017
Q3 | $72.1M | Buy |
9,793,809
+203,989
| +2% | +$1.3M | ﹤0.01% | 2056 |
|
|
2017
Q2 | $65.1M | Buy |
9,589,820
+66,767
| +0.7% | +$493K | ﹤0.01% | 2075 |
|
|
2017
Q1 | $89.9M | Buy |
9,523,053
+9,516,686
| +149,469% | +$95M | ﹤0.01% | 1851 |
|
|
2016
Q4 | $55K | Sell |
6,367
-236
| -4% | -$1.74K | ﹤0.01% | 2887 |
|
|
2016
Q3 | $42K | Buy |
6,603
+728
| +12% | +$4.4K | ﹤0.01% | 3051 |
|
|
2016
Q2 | $24K | Buy |
5,875
+1,696
| +41% | +$8.19K | ﹤0.01% | 3220 |
|
|
2016
Q1 | $19K | Buy |
4,179
+2,650
| +173% | +$11.8K | ﹤0.01% | 2887 |
|
|
2015
Q4 | $9K | Hold |
1,529
| – | – | ﹤0.01% | 2951 |
|
|
2015
Q3 | $9K | Hold |
1,529
| – | – | ﹤0.01% | 2803 |
|
|
2015
Q2 | $11K | Sell |
1,529
-389
| -20% | -$2.35K | ﹤0.01% | 2750 |
|
|
2015
Q1 | $11K | Hold |
1,918
| – | – | ﹤0.01% | 2701 |
|
|
2014
Q4 | $15K | Hold |
1,918
| – | – | ﹤0.01% | 2523 |
|
|
2014
Q3 | $10K | Hold |
1,918
| – | – | ﹤0.01% | 2747 |
|
|
2014
Q2 | $8K | Sell |
1,918
-63
| -3% | -$241 | ﹤0.01% | 2956 |
|
|
2014
Q1 | $8K | Buy |
1,981
+484
| +32% | +$2.48K | ﹤0.01% | 2880 |
|
|
2013
Q4 | $8K | Hold |
1,497
| – | – | ﹤0.01% | 2880 |
|
|
2013
Q3 | $8K | Hold |
1,497
| – | – | ﹤0.01% | 2810 |
|
|
2013
Q2 | $7K | Buy |
+1,497
| New | +$6.72K | ﹤0.01% | 2895 |
|
Other funds holding PGNX
BlackRock's PGNX Position: Q2 2020 in Review
BlackRock sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 13,850,498 shares — an estimated $52.6M sold.
BlackRock first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $91.6M in Q2 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.
- BlackRock reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
- BlackRock sold 13,850,498 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $52.6M.
- BlackRock first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
- BlackRock's Progenics Pharmaceuticals Inc position peaked at $91.6M in Q2 2018.
- 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.
Based on BlackRock's 13F filing for Q2 2020, filed 14 Aug 2020.